Selective Toxicity and Enhanced Therapeutic Index of Liposomal Polyene Antibiotics in Systemic Fungal Infections

Incorporation of the polyene antibiotic amphotericin B (AMB) in liposomes results in a marked reduction in drug toxicity with no loss of antifungal potency. Nephrotoxicity, the dose-limiting side effect of AMB, is almost abolished when the drug is utilized in a liposomal carrier. Because of reduced toxicity, high doses of liposomal AMB can be used, resulting in superior therapy of systemic fungal infections in mice. The improved therapeutic index of liposomal AMB versus free AMB is also manifest in infected neutropenic animals. The reduced toxicity of liposomal AMB is due to a fundamental alteration in the interaction of the drug with mammalian cell membranes. AMB transfers effectively from donor liposomes to fungal cell walls and membranes and is thus toxic to fungi. By contrast, AMB does not transfer from liposomes to mammalian cells and thus is not toxic to these cells. Thus, the use of liposomal AMB may offer a marked improvement in the therapy of systemic fungal infection in cancer patients and other immunodebilitated individuals.

[1]  G. Lopez-Berestein,et al.  Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells. , 1984, Biochimica et biophysica acta.

[2]  G. Lopez-Berestein,et al.  In vitro antifungal activities of amphotericin B and liposome-encapsulated amphotericin B , 1984, Antimicrobial Agents and Chemotherapy.

[3]  E. Hersh,et al.  Prophylaxis of Candida albicans infection in neutropenic mice with liposome-encapsulated amphotericin B , 1984, Antimicrobial Agents and Chemotherapy.

[4]  M. Murtaugh,et al.  Induction of tissue transglutaminase in mouse peritoneal macrophages. , 1983, The Journal of biological chemistry.

[5]  E. Hersh,et al.  Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. , 1983, The Journal of infectious diseases.

[6]  E. Hersh,et al.  The activation of human monocytes by liposome-encapsulated muramyl dipeptide analogues. , 1983, Journal of immunology.

[7]  R. Juliano,et al.  Interactions of liposomes with the reticuloendothelial system. II: Nonspecific and receptor-mediated uptake of liposomes by mouse peritoneal macrophages. , 1982, Biochimica et biophysica acta.

[8]  J. Graybill,et al.  Treatment of murine cryptococcosis with liposome-associated amphotericin B. , 1982, The Journal of infectious diseases.

[9]  R. Juliano,et al.  Interactions of liposomes with the reticuloendothelial system. Effects of reticuloendothelial blockade on the clearance of large unilamellar vesicles. , 1981, Biochimica et biophysica acta.

[10]  R. New,et al.  Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomes. , 1981, The Journal of antimicrobial chemotherapy.

[11]  Nichols Jw,et al.  Kinetics of soluble lipid monomer diffusion between vesicles. , 1981 .

[12]  L. Young.  Nosocomial infections in the immunocompromised adult. , 1981, The American journal of medicine.

[13]  Edwards Je,et al.  Severe Candidal Infections: Clinical Perspective, Immune Defense Mechanisms, and Current Concepts of Therapy , 1978 .

[14]  G. Bodey.  Infectious complications in the cancer patient. , 1977, Current problems in cancer.

[15]  G. Poste.  Liposome targeting in vivo: Problems and opportunities , 1983 .

[16]  J. Bolard,et al.  Antifungal agents useful in therapy of systemic fungal infections. , 1983, Annual review of pharmacology and toxicology.

[17]  E. Stiehm,et al.  Severe candidal infections: clinical perspective, immune defense mechanisms, and current concepts of therapy. , 1978, Annals of internal medicine.